Study wrapper · #1278
A microencapsulation strategy for intranasal semaglutide delivery.
Editor's note
A formulation feasibility study rather than a clinical one, with endpoints limited to encapsulation efficiency, storage stability and transport across cultured nasal cells. Those results are internally consistent and encouraging for the delivery route, but nothing here speaks to blood levels, bioavailability or weight outcomes in a living subject. Nasal peptide delivery has repeatedly failed at exactly the step this paper does not test, so read the results as a materials-science signal only.
Plain-language abstract
Researchers spray-dried semaglutide together with water-soluble polymers and trehalose to make a dry powder aimed at nasal delivery instead of injection. In laboratory testing the powder retained over 90% of its semaglutide after three months of storage, encapsulation efficiency exceeded 95%, the particles dissolved fully in nasal mucus within two hours, and they crossed nasal cell layers without measurable toxicity. This is early formulation work in cell culture; no animals or people were dosed.